SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGP

Biotechnology

Healthcare
$29.68 +2.49%

+$0.45 today

Market cap
$993.14M
Beta
-0.34
P/E (TTM)
-14.1
EPS (TTM)
-$1.32
52W Low $17.06High $32.44

Volume 0.10M

Average 0.09M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$32.70M

FY 2025 · Annual

Investing Cash Flow

-$11.79M

FY 2025 · Annual

Financing Cash Flow

$124.58M

FY 2025 · Annual

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$39.9M
+ D&A$612.0K
+ Stock-Based Comp$2.8M
+ Deferred Tax$0
+ Working Capital$2.4M
+ Other Non-Cash$1.3M
= Operating Cash Flow-$32.7M
- Capex-$789.0K
= Free Cash Flow-$33.5M

Analysis

FY2025 free cash flow is -$33.5M. FCF conversion is 84.0% of net income. Operating cash flow was -$32.7M, with capex of -$789.0K. The largest bridge item is Stock-Based Comp at $2.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
8-KCurrent reportOct 19, 2026
8-KCurrent reportOct 1, 2026
10-QQuarterly reportAug 6, 2026

Does SGP generate free cash flow?

SpyGlass Pharma, Inc. Common Stock (SGP) generated -$33.49M of free cash flow in fiscal 2025.

How much operating cash flow does SGP produce?

Operating cash flow was -$32.70M, before capital expenditures of $789,000.00.